Details

Autor(en) / Beteiligte

• Paton, Nicholas I
• Kityo, Cissy
• Hoppe, Anne
• Reid, Andrew
• Kambugu, Andrew
• Lugemwa, Abbas
• van Oosterhout, Joep J
• Kiconco, Mary
• Siika, Abraham
• Mwebaze, Raymond
• Abwola, Mary
• Abongomera, George
• Mweemba, Aggrey
• Alima, Hillary
• Atwongyeire, Dickens
• Nyirenda, Rose
• Boles, Justine
• Thompson, Jennifer
• Tumukunde, Dinah
• Chidziva, Ennie
• Mambule, Ivan
• Arribas, Jose R
• Easterbrook, Philippa J
• Hakim, James
• Walker, A. Sarah
• Mugyenyi, Peter

Titel

Assessment of Second-Line Antiretroviral Regimens for HIV Therapy in Africa

Ist Teil von

• The New England journal of medicine, 2014-07, Vol.371 (3), p.234-247

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2014

Quelle

MEDLINE

Beschreibungen/Notizen

• Appropriate second-line antiretroviral therapy for HIV infection is needed in resource-limited settings. In a comparison of three protease-inhibitor–based regimens in sub-Saharan Africa, the one that included nucleoside reverse-transcriptase inhibitors performed favorably. The public health approach of the World Health Organization (WHO), 1 together with large-scale donor funding, has enabled millions of adults and children in sub-Saharan Africa who are infected with the human immunodeficiency virus (HIV) to have access to lifesaving antiretroviral therapy. 2 The key principle is the use of simplified, standardized approaches that are feasible on a large scale in resource-limited settings, 1 , 3 including a first-line regimen of two nucleoside reverse-transcriptase inhibitors (NRTIs) plus one non-NRTI (NNRTI). In most settings, treatment is monitored clinically and with the use of CD4+ counts, with typically late detection of treatment failure, accompanied by substantial . . .